Research Materials Available to Fanconi Anemia Researchers
Background: To facilitate research into Fanconi anemia, the Fund has sponsored the development of affinity-purified rabbit polyclonal antisera against the Fanconi complementation group proteins. Ray Monnat, Jr., MD, University of Washington School of Medicine and a member of the Fund's Scientific Advisory Board, spearheads this effort.
These rabbit antisera were developed with a commercial partner, Open Biosystems in Huntsville Alabama, using peptide epitopes, and were validated by a combination of peptide ELISA assays and Western blot analyses with and without peptide blocking using cell lysates from different FANC protein-positive and negative human cell lines. All positive antisera were then affinity-purified and again titered by ELISA assay to determine sensitivity of detection. Antisera against eleven FANC proteins and USP1 are now available for distribution to all qualified investigators to further our understanding of Fanconi anemia biology.
Currently available antibodies:
Rabbit polyclonal affinity-purified antisera prepared against either peptide
epitopes or fusion protein antigens are available now to the following Fanconi
complementation group proteins: FANCA; FANCB; FANCC; FANCD1/BRCA2; FANCD2;
FANCE; FANCF; FANCG; FANCJ; FANCL (kindly provided for redistribution by
Dr. A. R. Meetei); and FANCM. Antisera are also available now for the deubiquinating
enzyme USP1. We anticipate antisera to FANCI and FANCN will be available
soon (Fall 2007).
Availability and Distribution:
The Fanconi Anemia Research Fund has contracted with Oregon Health &
Science University through the laboratory of Markus Grompe, MD, Department
of Medical and Molecular Genetics, to manage the FA Antibody Project in
conjunction with the FA Cell Repository already housed at OHSU. Xiaoman
Zhu, MD, is in charge of this project. An important part of this project
is the use and sharing of experience with these antisera with the Fanconi
community. Thus it is essential that all end users report their experience
on the best protocols and uses of specific antisera for immunofluorescence,
immunoprecipitation, Western blot or other analysis to help all users of
these antisera. This feedback can be entered on the Antibody website, where
it will be archived and made available to all users.
We will not honor
additional requests for reagents from users who do not provide feedback
on their experience using antisera.
The antisera listed above are available to all qualified non-commercial Fanconi anemia investigators via the FA Antibody Project website at http://www.ohsu.edu/fa. There is no charge for the antisera. Requesting investigators must complete a Use Agreement and Materials Transfer Form and provide a valid shipping account number to cover the cost of shipping. Commercial users may arrange to purchase the antisera via a distribution agreement with Open Biosystems. As noted above, an important aspect of this Project is to share use information. This is an essential aspect of this effort, and a requirement for receiving antisera.
Contact information:
Direct general inquiries regarding FANC antibodies to:
Ray Monnat, MD
Departments of Pathology and of Genome Sciences
University of Washington
Telephone: 206-616-7392
Fax: 206-543-3967
E-mail: monnat@u.washington.edu
Direct antibody distribution questions to:
Xiaoman Zhu, MD
Oregon Stem Cell Center
Oregon Health and Science University
Portland, OR
Telephone: 503-494-6889
Fax: 503-494-6886
E-mail: zhuxi@ohsu.edu
II. Antibodies Are Also Available from the Laboratory of Maureen Hoatlin, PhD, at Oregon Health and Science University (OHSU):
Contact:
Maureen Hoatlin, PhD
Division of Molecular Medicine and Molecular and Medical Genetics
Oregon Health and Science University
Portland, OR
Email: hoatlinm@ohsu.edu
Telephone: 503-494-1123; fax:
503-494-7368
Website: Hoatlin
Reagent Requests
|
I. Available from the Oregon Health and Science University (OHSU) Fanconi Anemia Cell Repository:
These cell lines
are available to all FA researchers. The Repository also has FA-D2
PD20 immortalized fibroblast cells that are retrovirally corrected
and is in the process of establishing retrovirally corrected immortalized
fibroblast cell lines from FA-A, FA-C, and FA-G complementation groups.
The
Repository can supply researchers with MEFs from FANCA (-/-) and FANCC
(-/-) knock out mice and, also, the double knock out FANCA/C (-/-).
Additionally, the Repository has wildtype (+/+) and heterozygote
FANCA (-/+) and FANCC (-/+) MEFs. Xiaoman
Zhu, MD |